Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY 4.0EULAR Rheumatology Open

The proportion of tuberculosis disease among adult patients receiving biologic agents at a tertiary centre in Kenya

  • Subo Hassan Marsa1
  • Fredrick Otieno Owuor1
  • Jasmit Shah1,2
  • Felix Riunga Mutuma1
  1. 1Department of Internal Medicine, Aga Khan University, Nairobi, Kenya
  2. 2Brain and Mind Institute, Aga Khan University, Nairobi, Kenya
Read full textDOICite

Abstract

Objectives: Tuberculosis (TB) remains a major global health challenge. Kenya is a high-TB burden country, with a prevalence of 558 cases per 100,000 adults according to the 2016 Kenya Tuberculosis Prevalence Survey. Biologic agents have been linked to an increased risk of TB infection due to their immunosuppressive effects. However, data on TB occurrence among patients receiving biologic agents in Kenya are lacking. This study aimed to determine the proportion of TB disease among adult patients receiving biologic agents at a tertiary centre in Kenya.

Methods: A retrospective cohort study of adult patients receiving biologic agents at Aga Khan University Hospital, Nairobi, between January 2018 and December 2023 was conducted. Data were extracted from the medical records of eligible patients using an abstraction tool, and statistical analysis was performed.

Results: A total of 204 patients were included. The median age was 45.8 years (IQR, 36.3-60.1), and 59.3% were female. Rheumatologic disorders were the most common indication for biologic therapy, followed by malignancies and neuroinflammatory disorders. Anti-CD20 agents, predominantly rituximab, accounted for 71.6% of biologic use. Only 69.1% of patients had pretreatment TB infection screening. Three patients (1.5%) developed TB disease, all while receiving rituximab.

Conclusions: All TB disease cases occurred during rituximab therapy, contrary to evidence emphasising a higher risk with anti-tumour necrosis factor alpha agents, highlighting the importance of systematic TB screening and monitoring across all biologic therapies in TB-endemic settings.

Related

  1. Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?
    Nagihan Orhan Özer, Betül Özdel Öztürk, Begüm Görgülü Akın +2
    Clinical and translational allergyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Disease Knowledge Assessed by RAKE-T and Its Sociodemographic and Clinical Correlates in Patients with Rheumatoid Arthritis Receiving Biologic and Targeted Synthetic DMARDs: A Multicenter Cross-Sectional Study
    Nihal Lermi, Eyyüp Garip, Abdullah Yusuf İstanbullu +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  3. Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre
    Marco Gerling, Carlos Fernández Moro, Celina Limbecker +13
    BMJ OpenPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Incidence and Predictors of QTC Prolongation Among Drug-Resistant Tuberculosis Patients Receiving Bedaquiline-Based TB Regimens in Uganda: A Countrywide Retrospective Cohort Study.
    Marble Nasasira, Kevin Ouma Ojiambo, Daniel Iraguha +1
    Open forum infectious diseasesPeer-reviewedCC BY-NC-NDFull textInfectious diseaseEurope PMC
  5. Digital Monitoring and Chronic Pain Trajectories in Patients Receiving Tertiary Pain Care
    Nicolas Kerckhove, Armel Soubeiga, Jules Phalip +7
    JAMA Network OpenPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyHAL

Cite

BibTeXRIS
BibTeX
@article{marsa2026proportion,
  title = {{The proportion of tuberculosis disease among adult patients receiving biologic agents at a tertiary centre in Kenya}},
  author = {Subo Hassan Marsa and Fredrick Otieno Owuor and Jasmit Shah and Felix Riunga Mutuma},
  journal = {EULAR Rheumatology Open},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ero.2026.100263},
  url = {https://doi.org/10.1016/j.ero.2026.100263},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The proportion of tuberculosis disease among adult patients receiving biologic agents at a tertiary centre in Kenya
AU  - Subo Hassan Marsa
AU  - Fredrick Otieno Owuor
AU  - Jasmit Shah
AU  - Felix Riunga Mutuma
PY  - 2026
DA  - 2026/10/26
JO  - EULAR Rheumatology Open
DO  - 10.1016/j.ero.2026.100263
UR  - https://doi.org/10.1016/j.ero.2026.100263
AB  - Objectives: Tuberculosis (TB) remains a major global health challenge. Kenya is a high-TB burden country, with a prevalence of 558 cases per 100,000 adults according to the 2016 Kenya Tuberculosis Prevalence Survey. Biologic agents have been linked to an increased risk of TB infection due to their immunosuppressive effects. However, data on TB occurrence among patients receiving biologic agents in Kenya are lacking. This study aimed to determine the proportion of TB disease among adult patients receiving biologic agents at a tertiary centre in Kenya.  Methods: A retrospective cohort study of adult patients receiving biologic agents at Aga Khan University Hospital, Nairobi, between January 2018 and December 2023 was conducted. Data were extracted from the medical records of eligible patients using an abstraction tool, and statistical analysis was performed.  Results: A total of 204 patients were included. The median age was 45.8 years (IQR, 36.3-60.1), and 59.3% were female. Rheumatologic disorders were the most common indication for biologic therapy, followed by malignancies and neuroinflammatory disorders. Anti-CD20 agents, predominantly rituximab, accounted for 71.6% of biologic use. Only 69.1% of patients had pretreatment TB infection screening. Three patients (1.5%) developed TB disease, all while receiving rituximab.  Conclusions: All TB disease cases occurred during rituximab therapy, contrary to evidence emphasising a higher risk with anti-tumour necrosis factor alpha agents, highlighting the importance of systematic TB screening and monitoring across all biologic therapies in TB-endemic settings.
SN  - 3050-7081
ER  -